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As reported: “A health care worker at Texas Health
Presbyterian Hospital, who cared for dying Ebola
patient has been tested positive for the virus after a
preliminary test, officials said early Sunday. If confirmed, it
would be the first known person-to-person transmission of
the disease in the United States” [1].
Every day people hear bad news around the distribution
of Ebola in Africa and also the possibility of its changing
to other continents. Coming up a successful remedy for
this horrible disease of the century is expected but inventing
and producing adequate medicines to be usable for the
increasing number of patients may have challenges.
The only available drug “Zmapp” has been produced by the
biotech firm “Mapp Biopharmaceutical Inc.”, which is based
in San Diego. “Mapp Biopharmaceutical” is working with
the “National Institutes of Health and the Defense Threat
Reduction Agency” that has followed to discover and
develop an Ebola medicine for several years [2].
Nevertheless, scientists think that casting out an untested
drug during an enormous outbreak would be really
hard. Furthermore, “Zmapp” is only a medicine under
evaluation and typically made in low amounts. On the
other hand, clinical trial and tracking the success of such
drugs requires more human resources and volunteers for
an excursion to the affected regions, whereas the number
of professional and medical staffs in those countries is
scarce and inadequate.
Despite the enormous attraction of research on the
Ebola drug discovery and development, running on this
virus is not simply accessed, because it requires biosafety
level 4-equivalent containment. Unfortunately, despite
high standards of security in such labs, research laboratory
workers are still at risk of contracting Ebola hemorrhagic
fever especially during animal experimentation. Until
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article, unless otherwise stated.documented in the literature and one of them led to
mortality [3]. That experimental medicine has been so
far administered to two American patients [4].
As of 1976 (the date of Ebola emerged), Ebola
hemorrhagic fever affected poor countries and such a
neglected diseases have not been a research priority for
pharmaceutical companies [4] but now it seems a real
research priority.Chronological history
Undoubtedly, Ebola epidemic in 2014 is the biggest
epidemic of this virus, so far, since multiple countries
in the West-Africa have been feigned. Established on
the present information, a few events have been reported
in Nigeria and a single case reported in Senegal but
fortunately not further spread in those lands. Nevertheless,
the first “travel-associated” case of Ebola was diagnosed in
the United States on September 30, 2014. As of the date of
writing this article, it is described that the US Center for
Disease Control and Prevention (CDC) and collaborators
are taking precautions to prevent the spread of Ebola within
the US in association with other governmental agencies,
the World Health Organization (WHO), as well as other
domestic and international collaborators. Furthermore,
CDC has outspread teams of health care professionals to
West-Africa and other affected countries [5].
Historically for the first time, Ebola (referred to the
figure of “Ebola River” in Zaire) was struck in Sudan
and Zaire (1976). Bibliography shows that the first
outbreak of Ebola (Ebola-Sudan) infected over 284
people (mortality rate: 53%), while the second Ebola
virus appeared in Yambuku, Zaire, Ebola-Zaire (EBOZ)
some months later with the highest mortality rate (88%),
infected 318 people. Notwithstanding the great efforts of
dedicated researchers so far, its natural reservoir has never
been set up. The third form of Ebola (Ebola Reston,
EBOR), was found in 1989 in infected monkeys that were
imported into Virginia from the Philippines. All the same,
a few individuals infected and never developed Ebola
hemorrhagic fever (EHF). The last known strain of Ebolaed Central Ltd. This is an Open Access article distributed under the terms of the
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during a necropsy on a dead chimpanzee from the Tai
Forest, Cote d’Ivoire. The etiologist who did necropsy
accidentally infected herself [6].
An overview of chronology of Ebola, published by US
CDC [5], expressed that the recent outbreak of Ebola
(2014) is the biggest epidemic in history because of the
multi-countries involved and tremendous number of
diagnosed patients (4655 people reported until the
date of this article) that unfortunately spread more.
Reservoirs of Ebola
Bats are known the most probably natural reservoirs of
Ebola virus, followed by plants, arthropods, and birds.
In the first epidemic, bats were found in the cotton
manufactory, in which the first cases of infection were
observed (1976, 1979). In reality, bats are the only infected
animals with no clinical signs among 24 plants and
19 vertebrate species that experimentally inoculated
with Ebola virus [7,8]. Moreover, fruit bats are used
by people in some fields of West-Africa as smoked
and grilled or even utilized in preparation of a spicy
soup. It is described that although transmission between
natural sources and humans rarely occur, outbreaks are
mostly originated from an individual who handles the
carcass of gorilla, chimpanzee or Duiker [9,10].
Virology of Ebola
The Ebola virus was thought to be a new strain of the
Marburg virus, but it was renamed “Ebola virus” in 2010
referred to the name of “Ebola River” in its original
country, Congo (formerly named Zaire). In fact, this
virus is just a single member of the species “Zaire
Ebolavirus” in the genus Ebolavirus, family Filoviridae.
The Zaire species of the Ebola virus are the most
dangerous, causing almost 90% mortality rate [11].
The genome of Ebola virus is a single-stranded RNA,
including about 19,000 nucleotides [12]. Ebolavirions
are filamentous particles that can be observed in a
shepherd’s crook or “U” or a “6” features, and also
they may be coiled, toroid, or branched. In addition,
Ebolavirions are 80 nm in width, while their length is
somewhat variable [13,14].
Pathophysiology of Ebola hemorrhagic fever
Literature reveals filoviruses have a broad spectrum cells
to target in susceptible host species, of which monocytes,
macrophages, dendritic cells (DCs), hepatocytes, adrenal
cortical cells, fibroblasts and endothelial cells. The
replication of virus is centered around the cells of the
mononuclear phagocyte system resulting in quick
circulation and widespread transferring throughout
the host body [15]. The Ebola virus glycoprotein (GP) is syn-
thesized in a secreted (sGP) or full-length transmembraneform, each of which well-defines its biochemical and
biological properties. GP is known to form a trimeric
complex (30) and binds to endothelial cells, while sGP
does not bind to epithelial cells. It forms a dimeric protein
that interferes with the signaling of neutrophils, and
therefore enables the virus to put off the immune system
through suppressing the early steps of neutrophil activation.
Infected neutrophils also act as carriers to transport the
virus throughout the body to locate like the lymph nodes,
liver, lungs, and spleen [15,16].
As literature shows, filoviruses are able to enter the
target cells through several uptake mechanisms such as
lipid raft-dependent and receptor-mediated endocytosis,
as well as macropinocytosis. When viruses fuse into
cellular membrane, nucleocapsids are released into the
cytoplasm and play a role of template for transcription
and replication. Concisely, the replicated RNAs are
encapsidated by the nucleocapsid proteins while nucleocap-
sids are transported to the locations of viral release, where
budding is ongoing. Viral assembling and budding might
happen either at intracellular membranes (multivesicular
budies) or at the plasma membrane [15,17]. As a matter of
fact, direct infection of monocytes and macrophages results
in releasing cytokines related to inflammation and
fever because of the host immune responses to Ebola
virus and cell damage. On the other side, infected
endothelial cells are able to induce a cytopathic damage to
the endothelial barrier that contributes to the loss of
vascular integrity, especially alongside the cytokine
effects [18].
Cell destination
Investigations of filovirus showed that they exploit the
infected cells to replicate successfully that potentially
may lead to cell destruction. Intriguingly, viruses exhibited
mechanisms to avoid cell death, because destroying
the infected cells inhibits the production of progeny
viruses. The mentioned mechanisms have been developed
through a complicated interaction between viruses and
cell death signaling pathways [19]. However, electron
microscopic studies and biochemical analyses of tissues
isolated from infected animals exhibited that infected
macrophages, dendritic cells, hepatocytes, and endothelial
cells did not develop apoptosis, since the cells looked
normal in morphological studies, whereas necrosis
was noted in some shells. These findings reveal that
filoviruses are able to control the cell death signaling
and pathways. For example, in Ebola infected cells,
the energizing of the PI3K/Akt signaling pathway can take
place very early leading to activation of Rac1, which is a
regulator of endocytosis and vesicular trafficking [15,20].
Filoviruses are known to interfere with antiviral signaling
pathways. The schematic diagram (Figure 1) summarized
some of these interventions.
Figure 1 Interactions of Ebola viruses with cell signaling pathways; EBOV: Ebola Virus; IFN: Interferons; NFkB: Nuclear factor
NF-kappa-B; PI3K/Akt: Phosphatidylinositol-3-Kinase and Protein Kinase B; PPRs: Peroxisome Proliferator-activated Receptors;
RIG-1: Retinoic acid-Inducible Gene 1; TLR4: Toll-Like Receptor 4.
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plays a role in cytotoxicity and cell damage, inducing
cell rounding and detachment as well as membrane
permeabilization. Furthermore, GP expression can
down-modulate the cell surface proteins such as
adhesion molecules, MHC class I proteins, and EGF
receptor. Literature demonstrated that the GP-induced
cytotoxicity may happen due to interaction of GP with the
GTPase dynamin, resulting in noise with the intracellular
trafficking of cell surface proteins [21]. On the other side,
lymphocytes (CD4 and CD8 T cells and Natural Killer
cells) do not support virus replication, likely due to the
lack of receptors, nevertheless they can develop apoptosis
while they are not tainted. A 17-mer in filovirus GPs has
recently been reported to induce lymphocyte death
and suppression of cytokine responses. This 17-mer is
responsible for resembling an immunosuppressive
motive. But the doubt, nevertheless remains that how
it is possible, since lymphocytes do not attach to the
viral GP? [22].
Prevention strategies
It is easily-documented that small interfering RNAs
(siRNAs) and phosphorodiamidate morpholino oligomers
(PMOs) could target Ebola virus RNA polymerase L
protein to prevent disease in nonhuman primates
[23,24]. These are some cases of advanced antisense
approaches for therapy of Ebola virus. Moreover,
TKM-Ebola and Sarepta Therapeutics are now being tested
in the Phase I clinical trial in humans [25]. ZMapp that has
been successfully used for two American patients is a
monoclonal antibody vaccine. As it was already reported,
the total supply of this medication is restricted and should
be under more investigations to gain significant results.Treatment
Although there is no specific approved medicine, early
supportive care, rehydration and symptomatic cures
such as using RBC, platelets or fresh frozen plasma, as
well as heparin to prevent disseminated intravascular
coagulation, and clotting agents to decrease bleeding
can be helpful [26]. Maintaining blood volume and
electrolyte balance as well as treating other bacterial
infections and dialysis may be employed [27].
Presently, there is no ground for using alternative
therapies or traditional medicine for prevention or
treatment of Ebola hemorrhagic fever. US FDA advises
people to be careful of advertisements for the benefits of
different anti-Ebola products [28]. Nevertheless, some of
antiviral drugs are now being considered. Among them,
favipiravir was already approved in Japan against influenza
pandemics. Literature revealed that this compound can be
efficient in vitro on Ebola infected mice. The most recent
news show that this drug has been successful in the
treatment of a French woman got Ebola in Liberia.
The woman received three experimental drugs for the
treatment that one of them was favipiravir [29,30].
BCX4430 (a broad-spectrum small molecule by BioCryst
Pharmaceuticals), brincidofovir (another broad-spectrum
antiviral granted an emergency FDA approval) and
lamivudine (an antiviral drug used to treat HIV/AIDS)
have recently been reported to show positive results
in treatment of Ebola-infected patients [31]. In fact,
due to the lack of available treatment, a number of
possible antiviral candidates that targeted against Ebola,
including both natural products (such as scytovirin
and griffithsin) and synthetic drugs (like FGI-103,
FGI-104, FGI-106, dUY11 and LJ-001) are presently
under investigation [32-34].
Figure 2 Possible sites of actions and targets for anti-Ebola drug discovery.
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tions, scientists could find a number of in vitro-effective
known drugs that are currently being used for other indica-
tions including ion channel blockers (for treatment of heart
arrhythmias) like amiodarone, dronedarone and verapamil,
which could block up the entry of Ebola virus into cells
[35]. In sum, the well-known selective estrogen receptor
modulators (clomiphene and toremifene) that are being
employed in therapy of infertility and breast cancer, have
been reported to suppress the progress of Ebola virus both
in vitro and in vivo [36]. Since these drugs are being used
orally and historically for other human illnesses, they can
be candidates for treatment of Ebola hemorrhagic fever in
the regions that are very far away alone or alongside other
antiviral medicines. Figure 2 shows the possible targets for
the future anti-Ebola drugs.
It seems that patients, who have rescued from Ebola
after infection, should possess strong immunity system
that acted faster than Ebola virus and restricted its
destroying activity. Therefore, synthetic or naturally
immunostimulats may help patients in combination
therapy with anti-Ebola medicines. Furthermore as
mentioned above, if estrogen receptor modulators (like
clomiphene) would probably be effective in clinical
trials, other phyto-estrogens from different classes of
secondary metabolites like isoflavonoids and phytosterls
could be candidates for in vitro and in vivo experi-
ments. Successfulness of natural proteins like “Scytovirin”
that is a cyanobacterial based (95-amino acid) antiviral
candidate leads scientists to another group of com-
pounds which could be produced through biotechnological
approaches.Conclusion
Although there is some information about the Ebola
virus and its interaction with infected or non-infected
cells, its target cells, stages of the replication cycle, and
its cytopathic effects, until now we are far from having
an efficient medication to control the virus outbreak. To
be prosperous in the founding of a medicine for Ebola,
the signaling pathways in the infected cells that contribute
in replication and fate must be better elucidated. There
are promising candidates in clinical trials for prevention of
the disease like DNA vaccines or vaccines derived from
adenoviruses, vesicular stomatitis Indiana virus (VSIV)
or filovirus-like particles (VLPs). These vaccines could
protect nonhuman primates from Ebola and hopefully
can be engaged in human [37-40].
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